You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline characteristics in the first-line switch-maintenance and second-line subgroups

From: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Characteristics 1 L-mn subgroup (n = 90) 2 L subgroup (n = 60)
Median age (IQR), years 59 (52.0–67.0) 62.5 (51.5–66.0)
Sex, n (%)
 Male 68 (75.6) 46 (76.7)
 Female 22 (24.4) 14 (23.3)
ECOG PS, n (%)
 0 37 (41.1) 23 (38.3)
 1 53 (58.9) 37 (61.7)
Geographic region, n (%)
 North America 31 (34.4) 32 (53.3)
 Asia 34 (37.8) 10 (16.7)
 Europe 25 (27.8) 18 (30.0)
Race, n (%)
 White 44 (48.9) 36 (60.0)
 Asian 35 (38.9) 13 (21.7)
 Black 4 (4.4) 4 (6.7)
 Other 7 (7.8) 7 (11.7)
Histology, n (%)
 Tubular 18 (20.0) 3 (5.0)
 Signet ring 17 (18.9) 13 (21.7)
 Mucinous 4 (4.4) 4 (6.7)
 Papillary 1 (1.1) 0
 Other/not specified 1 (1.1) 0
 Unknown 37 (41.1) 39 (65.0)
PD-L1 expression status based on ≥1% cutoff on tumor cells, n (%)
 PD-L1+ 26 (28.9) 20 (33.3)
 PD-L1− 51 (56.7) 25 (41.7)
 Not evaluable 13 (14.4) 15 (25.0)
HER2 status, n (%)
 HER2− 62 (68.9) 29 (48.3)
 HER2+ 4 (4.4) 5 (8.3)
 Unknown 24 (26.7) 26 (43.3)
Microsatellite status, n (%)
 Low 1 (1.1) 0
 Stable 21 (23.3) 17 (28.3)
 High 2 (2.2) 2 (3.3)
 Unknown 66 (73.3) 41 (68.3)
Prior gastrectomy, n (%) 24 (26.7) 14 (23.3)
Metastatic disease status at study entry, n (%)
 M0 5 (5.6) 2 (3.3)
 M1 85 (94.4) 58 (96.7)
Tumor size at baselinea
 Median (IQR), mm 33 (19–52) 44 (25–69.5)
 Unknown, n (%) 1 (1.1) 1 (1.7)
Best response to prior anticancer therapy, n (%)
 Complete response 0 1 (1.7)
 Partial response 25 (27.8) 8 (13.3)
 Stable disease 59 (65.6) 23 (38.3)
 Progressive disease 0 22 (36.7)
 Not evaluable or unknown 6 (6.7) 5 (8.3)
Prior anticancer therapy (any setting), n (%) 90 (100) 60 (100)
Number of prior lines of anticancer therapy for metastatic or locally advanced disease, n (%)
 0 1 (1.1) 5 (8.3)
 1 87 (96.7) 53 (88.3)
 2 2 (2.2) 1 (1.7)
 Unknown 0 1 (1.7)
Median prior lines (range) 1.0 (0–2) 1.0 (0–2)
Interval from end of prior chemotherapy to start of avelumab therapy
 Median (IQR), days 45 (35–64) 77 (49–135)
 Data missing, n (%) 8 (8.9) 15 (25.0)
  1. aSum of the longest diameters of target lesions
  2. Abbreviations: 1 L-mn first-line switch-maintenance, 2 L second line, ECOG PS Eastern Cooperative Oncology Group performance status, IQR interquartile range